FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Patients were in their early 50s on average, and some 80% were women. Nearly all were white (most participants were from ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Despite having a robust drug development pipeline, lupus remains far behind other rheumatic and autoimmune conditions for which dozens of targeted therapies have been developed. Addressing the ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

The Rheumatoid Arthritis Drugs/Therapeutics market revenue was $$ Million USD in 2022, grew to $$ Million USD in 2024, and will reach $$ Million USD in 2032, with a CAGR of $% during 2024-2032.

The global antibody discovery market size is anticipated to reach approximately USD 22,570 million by 2034, up from USD 9,570 ...

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies ...

We look forward to his continued partnership in his new role as a strategic advisor.” Dr. Banerjee added, "Artiva is leading ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...